Research and Development Investment: Teva Pharmaceutical Industries Limited vs ImmunityBio, Inc.

Teva vs. ImmunityBio: A Decade of R&D Investment Trends

__timestampImmunityBio, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201415950001488000000
Thursday, January 1, 2015114340001525000000
Friday, January 1, 2016265460002111000000
Sunday, January 1, 2017397780001848000000
Monday, January 1, 2018534180001213000000
Tuesday, January 1, 20191119970001010000000
Wednesday, January 1, 2020139507000997000000
Friday, January 1, 2021195958000967000000
Saturday, January 1, 2022248149000838000000
Sunday, January 1, 2023232366000953000000
Monday, January 1, 2024998000000
Loading chart...

Cracking the code

A Decade of R&D Investment: Teva vs. ImmunityBio

In the ever-evolving pharmaceutical landscape, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, Teva Pharmaceutical Industries Limited and ImmunityBio, Inc. have demonstrated contrasting R&D strategies. From 2014 to 2023, Teva's R&D expenses have shown a downward trend, decreasing by approximately 36% from their peak in 2016. In contrast, ImmunityBio has ramped up its R&D spending, increasing by over 14,500% during the same period. This divergence highlights Teva's strategic shift towards cost optimization, while ImmunityBio aggressively invests in pioneering therapies. As the pharmaceutical industry faces mounting pressure to deliver groundbreaking treatments, these investment patterns offer a glimpse into the strategic priorities of two key players. The data underscores the dynamic nature of R&D investment and its pivotal role in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025